Skip to main content

$0.310 0.030 (10.71%)

High

$0.31

Low

$0.29

Trades

582

Turnover

$291,413

Volume

965,700
30 June 2023 at 4:10pm
Register to track SPL and receive email alerts.
Subject
SPL Ann: Quarterly Cashflow and Activities Report

SPL Ann: Starpharma to present DEP at US Drug Delivery Conference

SPL Ann: VIRALEZE distribution and supply to Vietnam

SPL Ann: Notification regarding unquoted securities - SPL

SPL Ann: VIRALEZE ADMENTA agreement - supplementary information

SPL Ann: VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy

SPL Ann: Change in Director's Interest Notice - J Fairley

SPL Ann: Notification of cessation of securities - SPL

SPL Ann: 2021 Annual General Meeting

SPL Ann: US patent issued for DEP cabazitaxel nanoparticle

SPL Ann: Application for quotation of securities - SPL

SPL Ann: Change in Director's Interest Notice - Z Peach

SPL Ann: Change in Director's Interest Notice - J Fairley

SPL Ann: Change in Director's Interest Notice - R Thomas

SPL Ann: Change in Director's Interest Notice - L Cheng

SPL Ann: Appendix 4G - Corporate Governance Statement

SPL Ann: Starpharma annual report and full year financial results

SPL Ann: VIRALEZE Protects Against SARS-CoV-2 in Challenge Model

SPL Ann: VIRALEZE well tolerated in multiple dose clinical study

SPL Ann: Initial Director's Interest Notice

SPL Ann: Quarterly Cashflow and Activities Report

SPL Ann: Resignation of non-executive director

SPL Ann: Lynda Cheng appointed as non-executive director

SPL Ann: Starpharma to present DEP platform at CRS Annual Meeting

SPL Ann: VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant

SPL Ann: TGA infringement notices for alleged advertising

SPL Ann: Change in substantial holding

SPL Ann: Starpharma to present at Virtual Life Science Investor Forum

SPL Article: Another speed bump for Starpharma

SPL Ann: VIRALEZE UK Update

SPL Ann: VIRALEZE SPL7013 virucidal against multiple COVID variants

SPL Ann: VIRALEZE antiviral nasal spray registered for sale in India

SPL Ann: VIRALEZE SPL7013 highly active in UK variant of coronavirus

SPL Ann: VIRALEZE partners with Harlequins in the UK

SPL Ann: VIRALEZE launches in Europe

SPL Ann: Shareholder Newsletter

SPL Ann: Quarterly Cashflow and Activities Report

SPL Ann: Appendix 2A

SPL Ann: VIRALEZE now launched by LloydsPharmacy in the UK

SPL Ann: VIRALEZE to be launched with LloydsPharmacy in the UK

SPL Ann: DEP HER2-lutetium outperforms in human breast cancer model

SPL Ann: SPL7013 active against other pandemic coronaviruses

SPL Ann: Interim Report and Half-Year Financial Results

SPL Ann: VIRALEZE antiviral nasal spray registered in Europe

SPL Ann: Starpharma signs DEP ADC Research Agreement with MSD

SPL Ann: AZD0466 clinical DEP program global expansion

SPL Ann: Change in substantial holding

SPL Ann: Quarterly Cashflow and Activities Report

SPL Ann: Appendix 2A

SPL Ann: Change in substantial holding

Register to track SPL and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE